Clinical trials: Glaucoma, Open Angle
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease
A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a…
- Trial name
- NCT04133311
- Testing
- DE-130A, Xalatan®, DE-130A/DE-130A
- Where
- France
- Volunteers
- 386 people
- Sponsor
- Santen SAS
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Open-Angle Glaucoma, Ocular Hypertension
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma…
- Trial name
- NCT00918346
- Testing
- Tafluprost 0.0015%
- Where
- 3 sites in Finland, Germany
- Volunteers
- 43 people
- Sponsor
- Santen Oy
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate…
- Trial name
- NCT01426867
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 103 people
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG), Ocular Hypertension
Travoprost Five Day Posology Study
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
- Trial name
- NCT01114893
- Testing
- Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension.
- Trial name
- NCT01026831
- Testing
- Preservative-Free Tafluprost, Comparator: timolol
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUS (NCT02061683)
- Testing
- Bimatoprost 0.03%
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or…
- Trial name
- NCT01291108
- Testing
- AGN-210669, bimatoprost, bimatoprost vehicle
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
InnFocus MicroShunt Versus Trabeculectomy Study
Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma…
- Trial name
- IMS (NCT01881425)
- Testing
- Glaucoma Surgery, InnFocus MicroShunt
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 732 people
- Sponsor
- InnFocus Inc.